{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T10:57:11Z","timestamp":1785581831218,"version":"3.56.0"},"reference-count":50,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":41,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Alz &amp; Dem Diag Ass &amp; Dis Mo"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>INTRODUCTION<\/jats:title>\n                    <jats:p>Establishing interchangeability between cerebrospinal fluid (CSF) and positron emission tomography (PET) for patient identification may improve access to Alzheimer's disease (AD) therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>Alzheimer's Disease Neuroimaging Initiative participants with mild cognitive impairment or AD dementia and available CSF, florbetapir PET, and\/or flortaucipir PET were included. The interchangeability of CSF (per label threshold\/method) and PET was evaluated for patient identification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      Fujirebio Lumipulse amyloid beta (A\u03b2) 42\/A\u03b240 (\n                      <jats:italic>N\u00a0<\/jats:italic>\n                      =\u00a0288) and Roche Elecsys phosphorylated tau 181 (P\u2010tau181)\/A\u03b242 (\n                      <jats:italic>N<\/jats:italic>\n                      \u00a0=\u00a0251) Conformit\u00e9 Europ\u00e9ene (CE)\u2010marked CSF assays were in high agreement with and non\u2010inferior to florbetapir PET for identifying patients with AD pathology. High agreement was observed between Roche Elecsys CSF P\u2010tau181\/A\u03b242 (\n                      <jats:italic>N<\/jats:italic>\n                      \u00a0=\u00a0127) and an early (temporal) flortaucipir PET stratification.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DISCUSSION<\/jats:title>\n                    <jats:p>CSF assays were interchangeable with amyloid PET to identify patients with AD pathology and were in high agreement with elevated early temporal flortaucipir PET. CSF biomarkers may be used as a robust alternative to PET, potentially increasing access to AD diagnosis and disease\u2010modifying treatments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/dad2.70288","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T03:46:51Z","timestamp":1778644011000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Interchangeability of CSF and PET to identify Alzheimer's disease pathology"],"prefix":"10.1002","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4805-5193","authenticated-orcid":false,"given":"Samantha C.","family":"Burnham","sequence":"first","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupa K.","family":"Arora","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Iaccarino","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"},{"name":"Eli Lilly and Company  Sesto Fiorentino Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Kennedy","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Kotari","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameera R.","family":"Wijayawardana","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie M.","family":"Shaw","sequence":"additional","affiliation":[{"name":"Hospital of the University of Pennsylvania  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalya","family":"Benina","sequence":"additional","affiliation":[{"name":"Fujirebio Diagnostics Inc.  Malvern Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Lu","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Pontecorvo","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances\u2010Catherine","family":"Quevenco","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Zurich Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wang","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Alzheimer's Disease Neuroimaging Initiative","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"World Health OrganizationDementia. Accessed March 24 2025. Available athttps:\/\/www.who.int\/news\u2010room\/fact\u2010sheets\/detail\/dementia"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010021\u201001382\u2010x"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474\u20104422(21)00066\u20101"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.02.018"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13859"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.30"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.30"},{"key":"e_1_2_8_11_1","article-title":"Early Alzheimer's disease: developing drugs for treatment","author":"U.S. Department of Health and Human Services","journal-title":"Draft guidance, 2024 (Revision 2)"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph14020110"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43587\u2010022\u201000269\u2010x"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474\u20104422(16)00070\u20103"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp\u20102022\u2010329530"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2100708"},{"key":"e_1_2_8_17_1","unstructured":"U.S. Food & Drug Administration.510(k) Premarket notification. Alzheimer's disease pathology assessment test 510(k) number K221842. Accessed March 24 2025. Available athttps:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpmn\/pmn.cfm?ID=K221842"},{"key":"e_1_2_8_18_1","unstructured":"Cobas\u00ae.Elecsys \u03b2\u2010Amyloid (1\u201042) CSF II. Methods sheet. Accessed March 25 2025. Available athttps:\/\/elabdoc\u2010prod.roche.com\/eLD\/api\/downloads\/7a9a7998\u2010938e\u2010ee11\u20102191\u2010005056a772fd?countryIsoCode=nl"},{"key":"e_1_2_8_19_1","unstructured":"PET Acquisition.Alzheimer's Disease Neuroimaging Initiative (ADNI). Accessed 12 September 2023. Available athttps:\/\/adni.loni.usc.edu\/help\u2010faqs\/adni\u2010documentation\/"},{"key":"e_1_2_8_20_1","unstructured":"PET Pre\u2010Processing.Alzheimer's Disease Neuroimaging Initiative (ADNI). Accessed 12 September 2023. Available athttps:\/\/adni.loni.usc.edu\/help\u2010faqs\/adni\u2010documentation\/"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.114.153494"},{"key":"e_1_2_8_22_1","unstructured":"U.S. Food & Drug Administration.Florbetapir prescribing information. Accessed March 24 2025. Available athttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/202008s000lbl.pdf"},{"key":"e_1_2_8_23_1","unstructured":"European Medicines Agency.Summary of product characteristics. Amyvid INN\u2010florbetapir [18F]. Accessed March 24 2025. Available athttps:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/amyvid\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.06.1353"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awz090"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.200691"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.200006"},{"key":"e_1_2_8_28_1","unstructured":"U.S. Food & Drug Administration.Flortaucipir prescribing information. Accessed March 24 2025. Available athttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/212123s000lbl.pdf"},{"key":"e_1_2_8_29_1","unstructured":"European Medicines Agency.Summary of product characteristics.Tauvid INN\u2010Flortaucipir (18F). Accessed March 24 2025. Available athttps:\/\/www.ema.europa.eu\/en\/documents\/smop\u2010initial\/chmp\u2010summary\u2010positive\u2010opinion\u2010tauvid_en.pdf"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.0528"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195\u2010023\u201001160\u20106"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120\u2010025\u201000798\u20108"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/19466315.2016.1202859"},{"key":"e_1_2_8_34_1","unstructured":"U.S. Food & Drug Administration. Guidance document on non\u2010inferiority clinical trials (FDA\u20102010\u2010D\u20100075) issued by Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research. Accessed September 24 2025. Available athttps:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/non\u2010inferiority\u2010clinical\u2010trials"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD\u2010170128"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195\u2010020\u201000595\u20105"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.3180"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD\u2010200119"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12919"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51681"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD\u2010210593"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadm.2015.10.001"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12182"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadm.2018.07.002"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD\u2010170327"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12190"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1177\/25424823251362444"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.43"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195\u2010021\u201000834\u20103"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474\u20104422(12)70291\u20100"},{"issue":"1","key":"e_1_2_8_51_1","article-title":"Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum","volume":"14","author":"Dor\u00e9 V","year":"2022","journal-title":"Alzheimers Dement"}],"container-title":["Alzheimer's &amp; Dementia: Diagnosis, Assessment &amp; Disease Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dad2.70288","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/dad2.70288","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dad2.70288","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T09:57:48Z","timestamp":1785578268000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1002\/dad2.70288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1002\/dad2.70288"],"URL":"https:\/\/doi.org\/10.1002\/dad2.70288","archive":["Portico"],"relation":{},"ISSN":["2352-8729","2352-8729"],"issn-type":[{"value":"2352-8729","type":"print"},{"value":"2352-8729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"2025-03-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70288"}}